摘要
支气管哮喘（简称哮喘）是多基因参与的具有遗传易感性的慢性气道变应性炎症。胸腺基质淋巴细胞生成素（thymic stromal lymphopoietin，TSLP）是一种由上皮细胞产生的白介素7（IL-7）样细胞因子，与多种免疫细胞的TSLP受体相互作用，诱导Th2型免疫应答，参与哮喘的发生和发展。多个遗传学研究发现，哮喘是一种遗传易感性疾病，TSLP基因单核苷酸多态性与哮喘易感性密切相关，靶向TSLP治疗有望为今后哮喘免疫治疗带来新的前景。
Bronchial asthma is a chronic allergic airway inflammation of multiple genes involved in genetic susceptibility. Thymic stromal lymphopoietin（TSLP） is an epithelially derived cytokine, which is closely related to IL-7. TSLP interacts with a variety of immune cells through TSLPR,induction of Th2 inflammation and involved in the occurrence and development of asthma. A variety of genetic studies show that asthma is a genetic susceptibility disease. The single nucleotide polymorphisms（SNP） of TSLP was found closely related to the susceptibility to asthma. Targeting TSLP treatment is expected to bring new prospects for the future treatment of asthma.
出处
《国际呼吸杂志》
2012年第20期1575-1579,共5页
International Journal of Respiration
